OSLO, Norway--(BUSINESS WIRE)--Affitech AS, the human antibody therapeutics company announced today that its partner, Peregrine Pharmaceuticals, has reported that its anti-VEGF antibody R84, an antibody identified by Affitech, selectively blocks the interaction of vascular endothelial growth factor (VEGF) to VEGF receptor 2 (VEGFR2); and is as effective as Avastin® (bevacizumab) in inhibiting growth of established tumors in a preclinical breast cancer model. Results were presented at IBC’s 5th Annual International Anti-Angiogenesis Conference in Boston on November 12, 2007.
